ProfileGDS5678 / 1452107_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 84% 85% 82% 82% 77% 73% 75% 72% 87% 89% 84% 87% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.3173885
GSM967853U87-EV human glioblastoma xenograft - Control 26.3014384
GSM967854U87-EV human glioblastoma xenograft - Control 36.3391485
GSM967855U87-EV human glioblastoma xenograft - Control 46.0919782
GSM967856U87-EV human glioblastoma xenograft - Control 55.9916382
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1577
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5962373
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.9145875
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.6364672
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.6399987
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9932389
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.2887784
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.6141687
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.3357285